-
2 weeks ago | 
kevinmd.com | Dawn Baker |L. Joseph Parker |Rajarshi Banerjee |Michele Luckenbaugh
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!Psychiatrist Muhamad Aly Rifai discusses his article, “The future of psychiatry: How AI and genetics are reshaping mental health care.” Muhamad explores how the integration of genetic research, biomarkers, electrophysiology, and artificial intelligence is transforming psychiatry into a more precise and preventative field.
-
1 month ago | 
consultantlive.com | Rajarshi Banerjee
New research suggests multiparametric magnetic resonance imaging (mpMRI) with LiverMultiScan is a viable tool for identifying and managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), offering a cost-effective alternative to liver biopsy and other noninvasive tests.1 “Multiparametric MRI is a very great technology for tissue characterization, and since the diagnosis of MASH, metabolic associated steatohepatitis, is a tissue characterization diagnosis… the...
-
1 month ago | 
hcplive.com | Rajarshi Banerjee
New research suggests multiparametric magnetic resonance imaging (mpMRI) with LiverMultiScan is a viable tool for identifying and managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), offering a cost-effective alternative to liver biopsy and other noninvasive tests.1 “Multiparametric MRI is a very great technology for tissue characterization, and since the diagnosis of MASH, metabolic associated steatohepatitis, is a tissue characterization diagnosis… the...
-
1 month ago | 
medium.com | Rajarshi Banerjee
Rajarshi Banerjee·Follow4 min read·--The way we connect in business is evolving rapidly. With digital transformation accelerated by recent disruptions, the B2B event landscape is set for a remarkable shift over the next few years. In 2025–2026, hybrid models, immersive technologies, data-driven personalization, and sustainability will not only redefine event formats but also reshape business outcomes.
-
Dec 6, 2024 | 
kevinmd.com | Caitlin Ryus |Jeffrey Fraser |Stephen Parodi |Rajarshi Banerjee
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!We sit down with pulmonary and critical care physicians Tonya Jagneaux and Hollis O’Neal to explore the complex challenges emergency departments face when diagnosing and treating sepsis.
-
Nov 30, 2024 | 
kevinmd.com | Dawn Baker |L. Joseph Parker |Rajarshi Banerjee |Michele Luckenbaugh
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!We dive into the evolving landscape of treatment for restless legs syndrome (RLS) with neurologist Andrew Spector. For decades, patients have been prescribed dopamine agonists like ropinirole and pramipexole, often unaware that these medications could worsen their symptoms over time.
-
Oct 15, 2024 | 
lexology.com | Rajarshi Banerjee |Bradford Flint
Click here to listen to the audioOn this episode of the R&G Tech Studio podcast, host Brad Flint, co-leader of Ropes & Gray’s venture capital and emerging companies practice, is joined by Raj Banerjee, a partner in both the venture capital and emerging companies practice, as well as the IP transactions group at Ropes & Gray. Raj shares insights from his extensive experience as a life sciences lawyer, focusing on the intersection of AI and life sciences.
-
Jun 16, 2024 | 
kevinmd.com | Rajarshi Banerjee |Jeffrey Fraser |Sara Pastoor |Christopher Habig
The term “revolutionary” is used too often in health care. New imaging modalities, pharmaceutical breakthroughs, advanced medical devices, and artificial intelligence are all regularly proclaimed to be revolutionary to attract interest and attention. But those of us trained in medicine who work in these fields know that revolutions don’t happen—it takes 17 years for new research to reach the translational stage. In reality, the best we can hope for is a fast evolution of clinical practices.
-
Jun 14, 2024 | 
auntminnie.com | Rajarshi Banerjee
The recent FDA approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) medication marks a significant milestone in the adoption of medical imaging for identifying and monitoring patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe progression, metabolic dysfunction-associated steatohepatitis (MASH).
-
Aug 17, 2023 | 
lexology.com | Rajarshi Banerjee |Bradford Flint |Catherine Skulan
Click here to listen to the audioOn this episode of Ropes & Gray’s podcast series, The Sponsor’s Edge: Insights on Growth and Venture Investing, asset management counsel Catherine Skulan hosts the second of a two-part conversation between Brad Flint, partner and co-lead of Ropes & Gray’s venture investing & emerging companies practice, and Raj Banerjee, a senior associate in that practice.
